Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 Aug 24

PMID 28832023

Citations 40

Authors

K R Kelly

C M Espitia

W Zhao

K Wu

V Visconte

F Anwer

C M Calton

J S Carew

S T Nawrocki

Affiliations

Soon will be listed here.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.

REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity.

Carew J, Espitia C, Sureshkumar S, Carrera Espinoza M, Gamble M, Wang W Cancer Lett. 2025; 613:217496.

PMID: 39892703 PMC: 11832319. DOI: 10.1016/j.canlet.2025.217496.

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.

Dona A, Tandoh T, Nigam L, Singer M, Caserta E, Murtadha M J Hematol Oncol. 2025; 18(1):1.

PMID: 39828738 PMC: 11744858. DOI: 10.1186/s13045-024-01645-3.

Virus nanotechnology for intratumoural immunotherapy.

Omole A, Zhao Z, Chang-Liao S, de Oliveira J, Boone C, Sutorus L Nat Rev Bioeng. 2024; 2(11):916-929.

PMID: 39698315 PMC: 11655125. DOI: 10.1038/s44222-024-00231-z.

Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients.

Raimondi V, Vescovini R, Dessena M, Donofrio G, Storti P, Giuliani N Front Immunol. 2024; 15:1483806.

PMID: 39539548 PMC: 11557349. DOI: 10.3389/fimmu.2024.1483806.

References

Ray A, Das D, Song Y, Richardson P, Munshi N, Chauhan D . Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015; 29(6):1441-4. PMC: 5703039. DOI: 10.1038/leu.2015.11. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Kelly K, Espitia C, Zhao W, Wendlandt E, Tricot G, Zhan F . Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015; 6(38):41275-89. PMC: 4747405. DOI: 10.18632/oncotarget.5753. View

Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A . Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2012; 27(2):464-72. DOI: 10.1038/leu.2012.213. View

Benson Jr D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B . The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116(13):2286-94. PMC: 3490105. DOI: 10.1182/blood-2010-02-271874. View

Gorgun G, Samur M, Cowens K, Paula S, Bianchi G, Anderson J . Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015; 21(20):4607-18. PMC: 4609232. DOI: 10.1158/1078-0432.CCR-15-0200. View

Oyajobi B, Munoz S, Kakonen R, Williams P, Gupta A, Wideman C . Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther. 2007; 6(6):1701-8. PMC: 4482358. DOI: 10.1158/1535-7163.MCT-07-0121. View

Lesokhin A, Ansell S, Armand P, Scott E, Halwani A, Gutierrez M . Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016; 34(23):2698-704. PMC: 5019749. DOI: 10.1200/JCO.2015.65.9789. View

10.

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

11.

Kelly K, Espitia C, Mahalingam D, Oyajobi B, Coffey M, Giles F . Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2011; 31(25):3023-38. DOI: 10.1038/onc.2011.478. View

12.

Sborov D, Nuovo G, Stiff A, Mace T, Lesinski G, Benson Jr D . A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res. 2014; 20(23):5946-55. PMC: 4253985. DOI: 10.1158/1078-0432.CCR-14-1404. View

13.

Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D . Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007; 110(1):296-304. DOI: 10.1182/blood-2006-10-051482. View